Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 31/March/2019, 8.50 am

Intracardiac injection of Erythropoietin/Hematopoietin promotes heart regeneration and repair: Intracardiac injection of Erythropoietin/Hematopoietin decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 30/March/2019, 12.20 am
March 29, 2019
Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.02 am
March 31, 2019
Show all

Introduction: What they say:

A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, California 94305, USA Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California 94305, USA; Center for Tissue Regeneration, Repair and Restoration, V.A. Palo Alto Healthcare System, Palo Alto, California 94304, USA shows that “Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. This research paper was published, in the 19 April 2017 issue of the journal “Nature” [One of the best research journals in General sciences with an I.F of 43+], by Prof. Wyss-Coray, Castellano JM and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes


What is known?

Prof.Tony Wyss-Coray’s research team has recently shown that:  (1) human cord plasma treatment promotes cognitive and learning function in aged mice; (2) blood-borne component Tissue inhibitor of metalloproteinases 2 (TIMP2) is enriched in human cord plasma, young mouse plasma, and young mouse hippocampi; (3) TIMP2 increases hippocampal-dependent cognition; and (4) treating brain slices with TIMP2 antibody inhibits long-term potentiation and prevents hippocampal function, suggesting that increasing the expression of TIMP2 in aged individuals may enhance learning and memory.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, LncRNA 00152 may aid in the improvement of learning, memory, and cognition.  LncRNA 00152, by increasing the expression of its target genes, may increase the levels of TIMP2. Thereby, it may: (1) increase the expression of genes that promote learning and memory; (2) cognition and learning; (3) improve spatial memory; and (4) promote hippocampal function (fig.1).

Figure1. Mechanistic insights into how  LncRNA 00152 functions as a positive regulator of learning, cognition, memory, and longevity. LncRNA PCGEM1, by increasing the expression of TIMP2, it increases learning and memory in aged individuals

Figure 2. LncRNA 00152 functions as learning/memory/cognitive/longevity-enhancer through induction of TIMP2

[/caption]

 

[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “LncRNA 00152 or its activators, either alone or in combination with other drugs, may be used to suppress the age-associated overall physiological decline of hippocampal function and improve cognition and memory (fig.2).


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  LncRNA 00152 increase the levels of TIMP2?

Amount: $500#

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,  Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 31/March/2019, 8.50 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.